Photocure (PHO) - Total Assets
Based on the latest financial reports, Photocure (PHO) holds total assets worth Nkr901.41 Million NOK (≈ $94.85 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Photocure - Total Assets Trend (2000–2025)
This chart illustrates how Photocure's total assets have evolved over time, based on quarterly financial data. Also see market value of Photocure for the company's overall valuation and market capitalisation.
Photocure - Asset Composition Analysis
Current Asset Composition (December 2025)
Photocure's total assets of Nkr901.41 Million consist of 54.6% current assets and 45.4% non-current assets. Review Photocure (PHO) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr238.89 Million | 33.8% |
| Accounts Receivable | Nkr74.92 Million | 10.6% |
| Inventory | Nkr44.37 Million | 6.3% |
| Property, Plant & Equipment | Nkr42.20 Million | 6.0% |
| Intangible Assets | Nkr79.19 Million | 11.2% |
| Goodwill | Nkr144.00 Million | 20.4% |
Asset Composition Trend (2000–2025)
This chart illustrates how Photocure's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See PHO stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Photocure's current assets represent 54.6% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 33.8% of total assets in 2025, up from 7.6% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is cash and equivalents at 33.8% of total assets.
Photocure Competitors by Total Assets
Key competitors of Photocure based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
Photocure - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.65 | 4.78 | 5.12 |
| Quick Ratio | 3.11 | 4.29 | 4.77 |
| Cash Ratio | 0.00 | 3.08 | 4.08 |
| Working Capital | Nkr268.44 Million | Nkr293.34 Million | Nkr333.27 Million |
Photocure - Advanced Valuation Insights
This section examines the relationship between Photocure's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -4.3% |
| Total Assets | Nkr707.06 Million |
| Market Capitalization | $144.74 Million USD |
Valuation Analysis
Below Book Valuation: The market values Photocure's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Photocure's assets decreased by 4.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Photocure (2000–2025)
The table below shows the annual total assets of Photocure from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr707.06 Million ≈ $74.40 Million |
-4.33% |
| 2024-12-31 | Nkr739.09 Million ≈ $77.77 Million |
+3.81% |
| 2023-12-31 | Nkr711.97 Million ≈ $74.92 Million |
-0.98% |
| 2022-12-31 | Nkr719.03 Million ≈ $75.66 Million |
-8.94% |
| 2021-12-31 | Nkr789.65 Million ≈ $83.09 Million |
+1.75% |
| 2020-12-31 | Nkr776.05 Million ≈ $81.66 Million |
+201.55% |
| 2019-12-31 | Nkr257.35 Million ≈ $27.08 Million |
+11.31% |
| 2018-12-31 | Nkr231.20 Million ≈ $24.33 Million |
-12.13% |
| 2017-12-31 | Nkr263.10 Million ≈ $27.69 Million |
-7.96% |
| 2016-12-31 | Nkr285.85 Million ≈ $30.08 Million |
+15.24% |
| 2015-12-31 | Nkr248.06 Million ≈ $26.10 Million |
-8.32% |
| 2014-12-31 | Nkr270.58 Million ≈ $28.47 Million |
-10.32% |
| 2013-12-31 | Nkr301.73 Million ≈ $31.75 Million |
-30.31% |
| 2012-12-31 | Nkr432.98 Million ≈ $45.56 Million |
-14.97% |
| 2011-12-31 | Nkr509.18 Million ≈ $53.58 Million |
-0.91% |
| 2010-12-31 | Nkr513.84 Million ≈ $54.07 Million |
+12.47% |
| 2009-12-31 | Nkr456.86 Million ≈ $48.08 Million |
+92.08% |
| 2008-12-31 | Nkr237.85 Million ≈ $25.03 Million |
-21.08% |
| 2007-12-31 | Nkr301.39 Million ≈ $31.72 Million |
-19.72% |
| 2006-12-31 | Nkr375.42 Million ≈ $39.51 Million |
+255.16% |
| 2005-12-31 | Nkr105.70 Million ≈ $11.12 Million |
-39.15% |
| 2004-12-31 | Nkr173.71 Million ≈ $18.28 Million |
-25.57% |
| 2003-12-31 | Nkr233.40 Million ≈ $24.56 Million |
-21.94% |
| 2002-12-31 | Nkr299.01 Million ≈ $31.46 Million |
-6.43% |
| 2001-12-31 | Nkr319.57 Million ≈ $33.63 Million |
-21.06% |
| 2000-12-31 | Nkr404.85 Million ≈ $42.60 Million |
-- |
About Photocure
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through two segments, Commercial Franchise and Development Portfolio. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It is also developing Cevira, a photodynamic drug-device combination pro… Read more